Download PDF
CC BY-NC-ND 4.0 · Semin Thromb Hemost 2019; 45(03): 275-284
DOI: 10.1055/s-0038-1668098
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Detecting Anti-IIa and Anti-Xa Direct Oral Anticoagulant (DOAC) Agents in Urine using a DOAC Dipstick

Job Harenberg
1   DOASENSE GmbH, Heidelberg, Germany
2   Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
,
Rupert Schreiner
3   Medical Care Center Dr. Limbach and Colleagues, Heidelberg, Germany
,
Svetlana Hetjens
4   Division of Biometry and Statistics, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
,
Christel Weiss
4   Division of Biometry and Statistics, Medical Faculty Mannheim, Ruprecht-Karls University Heidelberg, Mannheim, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
22 August 2018 (online)

   Permissions and Reprints

Abstract

The assessment of the anticoagulant effect of direct oral anticoagulants (DOACs) can be important for rapid medical decision-making, especially in patients needing immediate management. An assay that screens for the absence or presence of a DOAC would help accelerate treatment in these situations. Chromogenic and coagulation methods have several limitations, including limited accuracy, long turnaround time, and their need of specialized laboratories. Oral factor Xa and thrombin inhibitors are also eliminated by the kidneys and can be detected in patient urine samples using a single, rapid, sensitive, and patient-specific qualitative assay. In these tests, the presence or absence of a DOAC in urine can be identified by visually observing specific colors after a few minutes. Several studies have demonstrated the robustness and repeatability of these assays. The specific colors of the test strip also detect creatinine in the urine, which shows whether DOAC excretion is reduced, thus suggesting renal impairment. Persons with amblyopia may use a specific reader. Current indications for using the DOAC Dipstick test include emergency medical situations with severe bleeding and thrombotic events or before urgent major surgical interventions to accelerate medical decision-making.

Keywords

direct oral anticoagulants - anticoagulants - methods - mass spectrometry - urine
 

  • References

  • 1 Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost 2017; 117 (07) 1283-1288
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Ten Cate H, Henskens YM, Lancé MD. Practical guidance on the use of laboratory testing in the management of bleeding in patients receiving direct oral anticoagulants. Vasc Health Risk Manag 2017; 13: 457-467
    CrossrefPubMedGoogle Scholar
  • 3 Tripodi A, Marongiu F, Moia M. , et al. The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. Intern Emerg Med 2018; ( e-pub ahead of print ) DOI: 10.1007/s11739-018-1854-6.
    CrossrefPubMedGoogle Scholar
  • 4 Gosselin RC, Adcock DM, Bates SM. , et al. International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 2018; 118 (03) 437-450
    Article in Thieme ConnectPubMedGoogle Scholar
  • 5 Du S, Harenberg J, Krämer S, Krämer R, Wehling M, Weiss C. Measurement of non-vitamin K antagonist oral anticoagulants in patient plasma using Heptest-STAT coagulation method. Ther Drug Monit 2015; 37 (03) 375-380
    CrossrefPubMedGoogle Scholar
  • 6 Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis 2012; 23 (02) 138-143
    CrossrefPubMedGoogle Scholar
  • 7 Fenyvesi T, Jörg I, Weiss C, Harenberg J. Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time. Thromb Res 2003; 111 (1-2): 89-94
    CrossrefPubMedGoogle Scholar
  • 8 Eikelboom JW, Connolly SJ, Brueckmann M. , et al; RE-ALIGN Investigators. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med 2013; 369 (13) 1206-1214
    CrossrefPubMedGoogle Scholar
  • 9 Di Minno A, Spadarella G, Prisco D, Franchini M, Lupoli R, Di Minno MN. Clinical judgment when using coagulation tests during direct oral anticoagulant treatment: a concise review. Semin Thromb Hemost 2013; 39 (07) 840-846
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Poli S, Härtig F, Spencer C. , et al. Diagnostic accuracy of a novel chromogenic direct thrombin inhibitor assay: clinical experiences for dabigatran monitoring. Thromb Haemost 2017; 117 (12) 2369-2375
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Samuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest 2017; 151 (01) 127-138
    CrossrefPubMedGoogle Scholar
  • 12 Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with high-resolution mass spectrometry. Ther Drug Monit 2014; 36 (05) 597-605
    CrossrefPubMedGoogle Scholar
  • 13 Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost 2017; 43 (03) 277-290
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Douxfils J, Ageno W, Samama CM. , et al. Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians. J Thromb Haemost 2018; 16 (02) 209-219
    CrossrefPubMedGoogle Scholar
  • 15 Gosselin RC, Douxfils J. Measuring direct oral anticoagulants. Methods Mol Biol 2017; 1646: 217-225
    PubMedGoogle Scholar
  • 16 Mani H, Herth N, Kasper A. , et al. Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant. Ther Drug Monit 2014; 36 (05) 624-631
    CrossrefPubMedGoogle Scholar
  • 17 Bluecher A, Meyer Dos Santos S, Ferreirós N. , et al. Microfluidic coagulation assay for monitoring anticoagulant therapy in acute stroke patients. Thromb Haemost 2017; 117 (03) 519-528
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Ebner M, Birschmann I, Peter A. , et al. Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants. Crit Care 2017; 21 (01) 32
    CrossrefPubMedGoogle Scholar
  • 19 Poli S. Specific PoC Testing of Coagulation in Patients Treated With DOAC 1 (SPOCT-DOAC 1). https://clinicaltrials.gov/ct2/show/NCT02825394 . Accessed April 29, 2018
    PubMedGoogle Scholar
  • 20 Perosphere Technologies Inc. Perosphere Technologies' Broad-Spectrum POC Coagulometer. http://www.perospheretech.com/content/research/coagulometer.htm . Accessed April 29, 2018
    PubMedGoogle Scholar
  • 21 Harenberg J, Warttinger U, Hetjens S. , et al. Reliability and validity of point-of-care tests taken from urine samples of patients on therapy with Apixaban, Rivaroxaban and Dabigatran. Res Pract Thromb Haemost 2017; 1 (Suppl. 01) PB454
    PubMedGoogle Scholar
  • 22 Harenberg J, Du S, Krämer S, Weiss C, Krämer R, Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost 2015; 41 (02) 228-236
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Needleman SB, Porvaznik M, Ander D. Creatinine analysis in single collection urine specimens. J Forensic Sci 1992; 37 (04) 1125-1133
    PubMedGoogle Scholar
  • 24 Schreiner R, Hetjens S, Giese C. , et al. Determination of rivaroxaban, apixaban, edoxaban and dabigatran by liquid chromatography-tandem mass-spectrometry and chromogenic assays from urine samples of patients. Res Pract Thromb Haemost 2017; 1: PB491
    PubMedGoogle Scholar
  • 25 Harenberg J, Krämer S, Du S, Weiss C, Krämer R. Concept of a point of care test to detect new oral anticoagulants in urine samples. Thromb J 2013; 11 (01) 15
    CrossrefPubMedGoogle Scholar
  • 26 Harenberg J, Du S, Wehling M. , et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med 2016; 54 (02) 275-283
    CrossrefPubMedGoogle Scholar
  • 27 Du S, Weiss C, Christina G. , et al. Determination of dabigatran in plasma, serum, and urine samples: comparison of six methods. Clin Chem Lab Med 2015; 53 (08) 1237-1247
    PubMedGoogle Scholar
  • 28 Harenberg J, Du S, Krämer S. , et al. Novel methods for assessing oral direct factor Xa and thrombin inhibitors: use of point-of-care testing and urine samples. Semin Thromb Hemost 2013; 39 (01) 66-71
    PubMedGoogle Scholar
  • 29 Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016; 14 (05) 886-893
    CrossrefPubMedGoogle Scholar
  • 30 In Vitro Diagnostic Testing for Direct Oral Anticoagulants, October 26, 2015. Available at: http://regulatorydoctor.us/wp-content/uploads/2015/11/IVD-Testing-for-Direct-Oral-Anticoagulants-October-26-2015.pdf . Accessed July 22, 2018
    PubMed
  • 31 Harenberg J, Ahrens F, Bauersachs R. , et al. A qualitative point of care test to assess anticoagulant activity in urine samples of patients treated with non-vitamin-K antagonist oral anticoagulants – a German consensus. J Thromb Haemost 2015; 13: 636-637
    PubMedGoogle Scholar
  • 32 Favaloro EJ, Lippi G. Interference of direct oral anticoagulants in haemostasis assays: high potential for diagnostic false positives and false negatives. Blood Transfus 2017; 15 (06) 491-494
    PubMedGoogle Scholar